Ardelyx (ARDX) Resubmits New Drug Application to FDA.
WALTHAM, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
And we Have Another Triple! Ardelyx (ARDX) Touches $5.00, up 333%.
LIVE QUOTE
Longer Term Chart
Ardelyx Enters the Danger Zone* With Tenapanor.
Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment...
Topline Results anticipated by the end of Q2 2023
CRANFORD, N.J. , April 3, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or...
Unicycive Therapeutics (UNCY) $2.73 Tacks on Another 30%. We’re now up 249%.
Quick way to Jinx Things...
Stormin..Live Quote
We're still not...
Unicycive (UNCY) Shoots and Scores, up 40% Today!
We're up 126% Since December, and That Ain't Bad.
Note: This isn't the end, it's just the...
Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update
$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024
Ohio State University Completes Study on Pressure Bioscience (PBIO) and Protein Drinks.
Pressure BioSciences' Ultra Shear Technology Positioned for Critical Enabling Role in Global $41 Billion (2027) Plant Protein Beverage Market.
Interview: Ric Schumacher CEO, Pressure Bioscience (PBIO)
Our favorite interview to date, and there have been dozens. Filmed November of 2021, and the story has gotten to much better...
Latest article
Selling Under Cash. LQR House (LQR) Addresses Nasdaq Delisting.
If You're a Sophisticated Speculator, and we do Mean Sophisticated, Study LQR House (LQR) or 'the Liquor House' Story.
LQR House (LQR). And the Numbers are In!
A Situation Which Can't be Ignored!
That's not to say run out and buy it, but this current valuation...
LQR Announces Proposed Reverse Split as Part of Nasdaq Compliance Plan
LIVE QUOTE
MIAMI BEACH, FL / ACCESSWIRE / November 21, 2023 / LQR House Inc....
